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Abstract 
BACKGROUND:  
Bone marrow (BM) histology/immunohistochemistry, KIT D816V mutation analysis and 
serum tryptase measurements are mandatory tools for diagnosis of systemic mastocytosis 
(SM).  
MATERIALS AND METHODS: 
Within the ‘German Registry of Disorders on Eosinophils and Mast Cells’, we identified 65 
SM patients who had two consecutive BM biopsies. The first biopsy was evaluated by a local 
pathologist (LP), the second biopsy by a reference pathologist (RP) of the ´European 
Competence Network on Mastocytosis (ECNM)´.   
RESULTS: 
Final diagnoses by RP were SM (n = 27), SM or aggressive SM (ASM) with associated non-
mast cell lineage hematologic disease [(A)SM-AHNMD, n = 34)] or mast cell leukemia ± 
AHNMD (n = 4). In 15/65 patients (23%), initial diagnoses by LP were incorrect (by 
overlooking SM), e.g. primary myelofibrosis (n = 3), myelodysplastic/myeloproliferative 
neoplasm unclassified (n = 3), B-cell lymphoma (n = 2). Fourteen of 15 patients (93%) with 
incorrect diagnosis had an advanced SM, mostly (A)SM-AHNMD. In the 50 concordantly 
diagnosed patients, immunohistochemical markers for quantitative assessment of mast cell 
infiltration, e.g. CD117 (KIT) or CD25, were applied by LP in only 34/50 patients (68%), and 
mutational analysis for KIT D816V was performed or recommended in only 13/50 patients 
(26%). Finally, the subclassification of SM was discordant because LP did not diagnose 
AHNMD in 9/50 (18%) patients.  
CONCLUSIONS: 
In summary, adequate diagnosis and subclassification of SM requires an in-depth evaluation 
of the BM by experienced hematopathologists (preferably in a reference center) in 
combination with molecular genetics, serum tryptase and clinical parameters. 
 
Introduction 
Systemic mastocytosis (SM) is a rare hematological disorder characterized by an increase and 
focal accumulation of tissue mast cells (MC) in various organ-systems, predominantly skin, 
bone marrow (BM) and visceral organs. The type and degree of organ infiltration as well as 
subsequent organ damage represent the basis for the classification of SM into indolent SM 
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(ISM), smoldering SM (SSM), SM with an associated clonal hematologic non-MC-lineage 
disease (SM-AHNMD), aggressive SM (ASM), and mast cell leukemia (MCL) [1-3]. 
Advanced SM is associated with a poor prognosis, with a median overall survival (OS) of 
approximately 0.5, 2, and 3.5 years for patients with MCL, SM-AHNMD and ASM, 
respectively [3]. An acquired mutation in the receptor tyrosine kinase KIT, usually KIT 
D816V, is detectable in over 80-90% of all SM patients [4, 5]. AHNMD usually presents as a 
myeloid neoplasm such as chronic myelomonocytic leukemia (CMML), 
myelodysplastic/myeloproliferative neoplasm unclassified (MDS/MPNu) or chronic 
eosinophilic leukemia (CEL) and frequently reflects the multilineage involvement of KIT 
D816V. The presence of additional mutations, most frequently TET2, SRSF2, ASXL1 or 
RUNX1, has recently been reported in a vast majority of patients with advanced SM [6-8]. 
These mutations usually precede KIT D816V and are associated with a more dismal 
prognosis [7, 9-11]. 
 
A thorough histological and immunohistochemical examination of the BM is recommended 
for the diagnosis and classification of SM. According to the World Health Organization 
(WHO) classification, diagnosis requires one major (multifocal compact MC infiltration) and 
one of four minor or three minor criteria, which include 1) atypical MC morphology (> 25% 
spindle shaped), 2) aberrant MC immunophenotype (expression of CD25/CD2), 3) activating 
mutations at codon 816 of KIT, predominantly KIT D816V, or 4) persistent elevation of 
baseline serum tryptase levels (> 20 ng/ml) [12]. 
 
MC-related immunohistochemical markers, including tryptase and CD117 (KIT), represent 
powerful tools for the identification and quantification of MCs in the BM or other tissues, 
which may be more difficult when applying (only) conventional stains, like hematoxylin and 
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eosin (H&E) or Giemsa, particularly in the presence of an AHNMD (Figure 1) [13]. 
Moreover, immunostaining enables detection of small but diagnostic compact MC infiltrates 
in some cases of SM. CD25 is a reliable marker for the differentiation between 
normal/reactive and neoplastic MCs because aberrant expression of this antigen is highly 
specific for SM and is seen in almost all patients and subtypes of SM [14]. The diagnosis of 
AHNMD is established by using WHO criteria, and is confirmed by evaluating peripheral 
blood (PB) and BM using additional immunological markers such as CD14 (monocytes), 
CD34 (progenitor/blast cells), CD61 (megakaryocytes), E-cadherin (erythroblasts) and 2D7 
(basophils and immature eosinophils) [15]. In this study, we sought to retrospectively 
evaluate the concordance of diagnosis and classification of SM by comparing morphological, 
immunohistochemical and molecular analyses in two consecutively performed BM trephine 
biopsies in 65 patients with KIT D816V+ SM.  
 
 
Materials and methods 
Patients 
In this retrospective analysis (between 2006-2014), we evaluated 65 SM patients (male 65%, 
median age 64 years, range 40-85) who had two consecutive BM biopsies. The initial biopsy 
was evaluated by a local pathologist (LP, mostly academic hematopathologists), while the 
second biopsy was evaluated by a specialized (reference) pathologist (RP) (H.-P.H. or K.S.) 
in an ´European Competence Network on Mastocytosis (ECNM)’ reference center for 
hematopathology. The median time between the two biopsies was 6 months (range 1-48). 
Second biopsies were performed in cases with an insufficient or inaccurate initial report by 
LP or a clear discrepancy between clinical symptoms, laboratory abnormalities or molecular 
characteristics and morphologic diagnosis by LP.  
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Bone marrow histology/immunohistochemistry by RP 
Conventional stains, such as Giemsa, Gömöri’s silver impregnation and naphthol AS-D 
chloroacetate esterase were applied to all trephine specimens. Sections were immunostained 
using the avidin–biotin complex method with antibodies against various antigens associated 
with MCs (tryptase, CD25, and CD117), stem cells (CD34), myelomonocytic cells 
(myeloperoxidase, lysozyme, CD15, and CD68), megakaryocytes (CD61), erythroblasts (E-
cadherin) and basophils/immature eosinophils (2D7) (Table 1).  
 
For this analysis, SM and ASM were summarized because they can not be differentiated by 
morphologic findings in the BM but only by the presence or absence of characteristic clinical 
features (C-findings) which include cytopenia(s) with an absolute neutrophil count < 1 x 
10
9
/L, hemoglobin < 10.0 g/dL and/or platelets < 100 x 10
9
/L, hepatomegaly with impaired 
liver function, palpable splenomegaly with signs of hypersplenism, malabsorption with 
significant hypoalbuminemia and/or significant weight loss > 10% over the last 6 months and 
osteolyses [1].  
 
KIT D816V and serum tryptase level  
For the qualitative and quantitative assessment of KIT D816V at the RNA-level (expressed 
allele burden, EAB), allele-specific quantitative real-time polymerase chain reaction analysis 
(RQ-PCR) was performed in PB or BM as previously described [4]. The presence of KIT 
D816V mutations in BM trephine biopsies was investigated as previously described [16]. 
Serum tryptase levels were measured by ImmunoCap Tryptase (Phadia Laboratory Systems, 
Uppsala, Sweden) and were available in 59/65 (91%) patients. 
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Statistical analysis  
All statistical analyses considered clinical and laboratory parameters obtained at time of 
diagnosis or first referral to our center that in most instances, coincided with time of BM 
biopsy and study sample collection. For categorical variables, two patient groups were 
compared with the exact Fisher test. P-values < 0.05 were considered significant. SPSS 
version 22.0.0 (IBM Corporation) were used for statistical analysis.  
 
Results 
Evaluation by RP 
Final diagnoses by RP were SM (n = 27), (A)SM-AHNMD (n = 34), MCL (n = 3) and MCL-
AHNMD (n = 1). AHNMD included CMML (n = 11), MDS/MPNu (n = 11), CEL (n = 5), 
myelodysplastic syndrome (MDS, n = 4), primary myelofibrosis (PMF, n = 1), acute myeloid 
leukemia (AML, n = 1), polycythemia vera (PV, n = 1) and chronic lymphocytic leukemia 
(CLL, n = 1). All patients with (A)SM/MCL-AHNMD fulfilled the major diagnostic criterion 
of multifocal dense infiltrates of MCs. Quantitative assessment of the extent of MC 
infiltration (tryptase, CD117, CD25) was reported in all patients (median 25%, range 5-90). 
Concomitant reticulin fibrosis and eosinophilia was observed in 41/65 (64%) and 48/65 
(74%) patients, respectively. KIT D816V mutational analysis was performed and positive in 
all 65 patients (Table 2). The serum tryptase level (normal value < 11.4 ng/ml) was elevated 
in 59/59 patients (median 132 ng/ml, range 12-1690).  
 
Evaluation by LP  
LP diagnosed SM in 50/65 (77%) patients: SM (n = 33), SM-AHNMD (n = 14) and MCL (n 
= 3). Diagnosis of AHNMD included CMML (n = 3), MDS (n = 3), PMF (n = 3), 
MDS/MPNu (n = 2), CEL (n = 1), PV (n = 1) and CLL (n = 1). MC infiltration was 
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quantified in 34/50 (68%, median 20%, range 5-90) patients. Immunohistochemistry was 
performed in 48/65 (74%) cases. CD117 (KIT) and CD25 was applied in 43/50 (86%) and 
24/50 (48%) cases, respectively. Fibre staining was performed in 45/65 (69%) cases and 
commonly associated reticulin fibrosis was observed in 32/45 (71%) cases. Eosinophilia was 
reported in 26/65 (40%) patients. KIT D816V mutational analysis was performed or 
suggested in 13/50 (26%) correctly diagnosed SM patients (Table 2).   
 
Characteristics of discordantly diagnosed patients 
Patients who were initially misdiagnosed (by missing SM) by LP (n = 15) experienced a 
median delay of 11 months (range 0-61 months) before a second diagnostic biopsy was 
obtained. In 8/15 patients (53%), the two biopsies were within 12 months. Discordant 
diagnoses by LP included PMF (n = 3), MDS/MPNu (n = 3), autoimmune thrombocytopenia 
(ITP, n = 2), indolent B-cell lymphoma (B-NHL, n = 2), CMML (n = 1), hypereosinophilic 
syndrome (HES, n = 1), anemia of chronic disease (ACD, n = 1) or without pathological 
findings (n = 2) (Figure 2).  
 
Fourteen of 15 patients (93%) with incorrect diagnosis had an advanced SM [(A)SM ± 
AHNMD, n = 12, MCL ± AHNMD, n=2). Eleven of the 15 (73%) discordantly diagnosed 
patients had an AHNMD including MDS/MPNu (n = 6), CMML (n = 3), MDS (n = 1) and 
CEL (n = 1). In two cases, AHNMD (CMML, n = 1; MDS/MPNu, n = 1) was correctly 
diagnosed by LP but without diagnosis of SM. The subclassification of SM was discordant 
because diagnosis of AHNMD was missed in 9/50 (18%) patients. The most frequently 
missed AHNMD were MDS/MPNu (n = 4) and CMML (n = 3) (Figure 2).   
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Significant differences (P < 0.001) between LP and RP regarding misdiagnosis, missing of 
AHNMD, quantification of MCs, immunohistochemistry, performance of fibre staining and 
mutational analysis are summarized in Table 2.   
 
Discussion 
In our retrospective analysis of 65 patients who have experienced two consecutive BM 
biopsies, we unraveled an unexpectedly high proportion of discordant diagnoses between 
local and reference pathologists of the ECNM, predominantly because of missed SM or 
missed AHNMD in otherwise correctly diagnosed SM. This data clearly emphasizes the 
importance of adequate immunohistochemical staining with tryptase, CD117 and CD25 for 
diagnosis of SM and CD34, CD14 plus other markers as indicated by the combination of PB 
counts (e.g. monocytosis or eosinophilia), serum tryptase and fluorescence activated cell 
sorting (FACS) analysis for diagnosis of AHNMD. Furthermore, the quantitative assessment 
of the extent of MC infiltration, which was performed by LP in only around two-thirds of 
patients, is an important complementary tool for subclassification and monitoring of 
response.  
 
The performance or even recommendation for mutational testing for KIT D816V in correctly 
diagnosed SM was also unexpectedly low. Qualitative and quantitative assessment of KIT 
D816V is extremely helpful to establish a correct diagnosis of SM, particularly in cases with 
only ambiguous BM MC infiltration or puzzling morphological findings. In addition, it is 
also useful for monitoring of response to treatment through recently established, highly 
sensitive techniques, which allow the detection of KIT D816V at levels down to 0.01% [4, 5, 
17]. In SM-AHNMD, the KIT D816V mutation is usually also identified in other lineages 
indicating SM-AHNMD as multilineage involvement of KIT D816V. The clinical 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
consequences of non-diagnosed KIT D816V+ SM or SM-AHNMD are dismal considering 
the inferior prognosis of advanced SM on one side and the recently emerging positive results 
of targeted treatment towards KIT-dysregulated hematopoiesis with tyrosine kinase 
inhibitors, e.g. midostaurin (PKC412), or allogeneic stem cell transplantation (ASCT) on the 
other side [3, 19].  
 
The frequently unspecific symptoms in combination with organ dysfunction (e.g. cytopenia, 
impaired liver function, malabsorption) may explain the broad range of differential 
diagnoses, including reactive conditions and neoplasms [15]. The complex clinical picture of 
SM patients highlights that disease-typical symptoms, alone but even more importantly in 
combinations, such as anaphylaxis plus osteoporosis, cytopenia plus gastrointestinal 
symptoms, monocytosis plus eosinophilia or eosinophilia plus retroperitoneal 
lympadenopathy should more frequently lead to the routine estimation of serum tryptase 
levels and KIT D816V mutation status in PB prior to BM biopsy. 
 
Obviously, one could argue that LP and RP should have analyzed the same biopsy and that at 
least in some of these patients, SM may just have developed shortly prior to the second 
biopsy. However, the interval between the two biopsies in three cases with incorrect 
diagnosis was less than 4 weeks and in all 9 patients with incorrect subclassification through 
missed AHNMD was only 1 to 8 months. All patients had to live with the incorrect diagnosis 
by LP, independently from the time interval between evaluation by LP and RP. Arguments 
that LP may have missed diagnosis due to low MC infiltration are counteracted by the fact 
that median BM MC infiltration in incorrectly diagnosed patients was 30% and advanced SM 
was diagnosed in 93% of patients. Several patients have even been treated for the incorrectly 
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diagnosed disease, e.g. bendamustin for indolent lymphoma, romiplostin for autoimmune 
thrombocytopenia or immunosuppressive treatment for hypereosinophilic syndrome.  
 
Recently, a study of the Spanish Network on Mastocytosis also compared diagnosis and 
classification of mastocytosis in non-specialized versus reference centres and showed similar 
results [20]. BM histology/immunohistochemistry, KIT D816V mutation analysis and serum 
tryptase are mandatory tools for diagnosis of SM. Although an elevated serum tryptase level 
and the presence of KIT D816V could easily be identified in PB in the vast majority of SM 
patients, particularly in advanced disease, both parameters are usually only measured in daily 
clinical routine following the diagnosis of SM by BM histology/immunohistochemistry. The 
central role of BM biopsy for diagnosis of SM should therefore be addressed through 
adequate use of relevant antibodies for identification and quantification of SM and SM-
AHNMD. A more frequent evaluation of serum tryptase and KIT D816V in PB would 
however help to reduce failure or delay the diagnosis of SM. Cases with (suspected) SM, 
based on clinical and/or morphological findings, should therefore always be (re-)assessed by 
a reference pathologist or ECNM-registered reference center for SM.  
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Table 1: Histology/immunohistochemistry and other diagnostic tools in need to reduce 
inaccurate, failure or delay of diagnosis in patients with (suspected) systemic mastocytosis. 
 
 
 
 
 
 
 
Diagnostic tools 
Histology/Immunohistochemistry 
 Staining (Giemsa, Gömöri’s silver impregnation and naphtol AS-D choloacetase 
esterase) 
 Various antigens (CD25, CD117, CD34, CD15, CD68, CD61, E-cadherin, 2D7, 
tryptase myeloperoxidase, lysozyme) 
 Optional: KIT D816V in bone marrow trephine biopsy 
Other  
 Serum tryptase level in peripheral blood 
 KIT D816V in peripheral blood or bone marrow (qualitative and quantitative) 
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Table 2: Findings of bone marrow (BM) biopsies by local pathologist (LP) and reference 
pathologist (RP). 
BM, bone marrow; PB, peripheral blood. 
 
 
 
 
BM histology 
LP 
n = 65 
(n, %) 
RP 
n = 65 
(n, %) 
P-value 
Final histological diagnosis    
 (A)SM 33 27  
 (A)SM-AHNMD 14 (22%) 34 (52%) < 0.001 
 MCL 3 3  
 MCL-AHNMD 0 1  
 other diagnosis (not SM) 15 (23%) 0 (0%) < 0.001 
Cellularity     
 hypercellular 48 54  
 normocellular 5 10  
 hypocellular 3 1  
 not reported 9 0  
Mast cells     
 increased 50 (77%) 65 (100%) < 0.001 
 quantified  
 median (range) 
34 (68%) 
20 (5-90) 
65 (100%) 
25 (5-90) 
< 0.001 
  normal 0 0  
 not reported 15 0  
Eosinophils    
 increased 26 (40%) 48 (74%) < 0.001 
 normal 0 0  
 not reported 39 17  
Immunohistochemistry     
 performed 48 (74%) 65 (100%) < 0.001 
   CD117/Tryptase    
 positive 
 not performed 
43 (86%) 
5 
65 (100%) 
0 
 
   CD25    
 positive 24 (48%) 65 (100%)  < 0.001 
 not performed 24 0  
Fibre staining    
 performed 45 (69%) 65 (100%) < 0.001 
 fibrosis  32 (71%) 41 (64%)  
Molecular markers    
 KIT D816V    
 performed (positive: n, %) 13 (13, 100%) 65 (65, 100%) < 0.001 
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Figure legends 
 
Figure 1: Systemic mastocytosis, aggressive subtype, with an associated, hematological non-
mast cell (myeloid) neoplasm (SM-AHNMD). Extremely hypercellular bone marrow with 
subtotal depletion of fat cells and diffuse increase in eosinophilic granulocytes at all stages of 
maturation (Figs. H&E, Giemsa). Immunohistochemistry discloses large compact infiltrates 
consisting of round mast cells with coexpression of CD25, CD117 (KIT) and tryptase. Note 
that Tryptase is not expressed by all mast cells and then often to a lesser intensity than 
CD117 (Figs. CD117, Tryptase). Expression of CD25 defines an aberrant immunophenotype 
of the mast cells (Fig. CD25). The antibody 2D7 detects a basophil-related antigen and 
depicts a cell cluster in the immediate vicinity of a compact mast cell infiltrate (Fig. 2D7). 
The final diagnosis could read as follows: ASM-HES. Altogether, this is a very challenging 
diagnosis and only possible after thorough immunohistochemical analysis.  
 
Figure 2: Circos diagram: pairwise linking between diagnosis assigned by local pathologist 
(LP, left) vs. reference pathologist (RP, right). The width of the ribbon/column correlates to 
the relative frequency of individual diagnosis. ACD, Anemia of chronic disease; B-NHL, B-
cell non-Hodgkin lymphoma; (A)SM, (aggressive) systemic mastocytosis; (A)SM-AHNMD, 
(A)SM with associated clonal hematologic non-mast cell lineage disease; CMML, chronic 
myelomonocytic leukemia; MDS/MPNu, myelodysplastic/myeloproliferative neoplasm 
unclassified; HES, hypereosinophilic syndrome; IMF, idiopathic myelofibrosis; ITP, 
autoimmune thrombocytopenia; MCL,  mast cell leukemia; u.a., without pathological 
findings. 
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